ClinVar Miner

Submissions for variant NM_183235.3(RAB27A):c.514_518del (p.Gln172fs)

dbSNP: rs767481076
Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 5
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
CeGaT Center for Human Genetics Tuebingen RCV001090830 SCV001246577 pathogenic not provided 2018-07-01 criteria provided, single submitter clinical testing
Invitae RCV000477784 SCV001384103 pathogenic Griscelli syndrome type 2 2023-10-14 criteria provided, single submitter clinical testing This sequence change creates a premature translational stop signal (p.Gln172Asnfs*2) in the RAB27A gene. While this is not anticipated to result in nonsense mediated decay, it is expected to disrupt the last 50 amino acid(s) of the RAB27A protein. This variant is present in population databases (rs767481076, gnomAD 0.006%). This premature translational stop signal has been observed in individual(s) with Griscelli syndrome (PMID: 10835631, 12648328, 23160464, 25312756, 25901543, 30697212). It has also been observed to segregate with disease in related individuals. This variant is also known as 510 del AAGCC. ClinVar contains an entry for this variant (Variation ID: 417958). This variant disrupts a region of the RAB27A protein in which other variant(s) (p.Arg184*) have been determined to be pathogenic (PMID: 10835631, 15475639, 18397837, 19030707, 19953648). This suggests that this is a clinically significant region of the protein, and that variants that disrupt it are likely to be disease-causing. For these reasons, this variant has been classified as Pathogenic.
Genomics Facility, Ludwig-Maximilians-Universität München RCV000477784 SCV002073885 pathogenic Griscelli syndrome type 2 2021-12-28 criteria provided, single submitter clinical testing
PreventionGenetics, part of Exact Sciences RCV003983090 SCV004800104 pathogenic RAB27A-related condition 2024-01-19 criteria provided, single submitter clinical testing The RAB27A c.514_518del5 variant is predicted to result in a frameshift and premature protein termination (p.Gln172Asnfs*2). In the literature this variant is also referred to as c.510delAAGCC and c. c.510-514delAAGCC. This variant has been reported in the homozygous and presumed homozygous states in individuals from consanguineous families with Griscelli syndrome, familial hemophagocytic lymphohsitiocytosis (FHL), and primary immunodeficiency disorders (Menasche et al. 2000. PubMed ID: 10835631; Sarper et al. 2003. PubMed ID: 12648328; Mamishi et al. 2008. PubMed ID: 18350256; Cetica et al. 2014. PubMed ID: 25312756; Al-Herz et al. 2019. PubMed ID: 30697212). This variant is reported in 0.0053% of alleles in individuals of European (Non-Finnish) descent in gnomAD. Frameshift variants in RAB27A are expected to be pathogenic. This variant is interpreted as pathogenic.
Division of Human Genetics, Children's Hospital of Philadelphia RCV000477784 SCV000536923 likely pathogenic Griscelli syndrome type 2 2016-08-26 no assertion criteria provided research

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.